ArticleClinical & experimental metastasis2005
Trefoil factor family-3 is associated with aggressive behavior of colon cancer cells.
Article in Clinical & experimental metastasis, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 43 citations in OpenAlex.
- Inhibition of TFF3 improves the infiltration and function of CD8International journal of colorectal disease · 2025Article
- Machine learning-based identification of proteomic markers in colorectal cancer using UK Biobank data.Frontiers in oncology · 2024Article
- CD147 receptor is essential for TFF3-mediated signaling regulating colorectal cancer progression.Signal transduction and targeted therapy · 2021Article
- Pharmacological Inhibition of TFF3 Enhances Sensitivity of CMS4 Colorectal Carcinoma to 5-Fluorouracil through Inhibition of p44/42 MAPK.International journal of molecular sciences · 2019Article
- Trefoil factor 3 mediation of oncogenicity and chemoresistance in hepatocellular carcinoma is AKT-BCL-2 dependent.Oncotarget · 2017Article
- Diagnostic value evaluation of trefoil factors family 3 for the early detection of colorectal cancer.World journal of gastroenterology · 2017Article
- Expression of trefoil factors and TWIST1 in colorectal cancer and their correlation with metastatic potential and prognosis.World journal of gastroenterology · 2017Article
- Article
- Increased immunoexpression of trefoil factors in salivary gland tumors.Clinical oral investigations · 2014Article
- Serum trefoil factor 3 is a promising non-invasive biomarker for gastric cancer screening: a monocentric cohort study in China.BMC gastroenterology · 2014Article
- Reduced expression of TFF1 and increased expression of TFF3 in gastric cancer: correlation with clinicopathological parameters and prognosis.International journal of medical sciences · 2013Article
- Increased trefoil factor 3 levels in the serum of patients with three major histological subtypes of lung cancer.Oncology reports · 2012Article
- Validity of multiplex biomarker model of 6 genes for the differential diagnosis of thyroid nodules.Thyroid research · 2011Article
- Trefoil factor 3 is oncogenic and mediates anti-estrogen resistance in human mammary carcinoma.Neoplasia (New York, N.Y.) · 2010Article
- Differentiating the undifferentiated: immunohistochemical profile of medullary carcinoma of the colon with an emphasis on intestinal differentiation.Human pathology · 2009Article
- Trefoil factor-3 expression in human colon cancer liver metastasis.Clinical & experimental metastasis · 2009Article
- Physiological stress induces the metastasis marker AGR2 in breast cancer cells.Molecular and cellular biochemistry · 2007Article
- Induction of the adenoma-carcinoma progression and Cdc25A-B phosphatases by the trefoil factor TFF1 in human colon epithelial cells.Oncogene · 2006Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimTrefoil factor family 3 (TFF3) is expressed by intestinal epithelial cells and it mainly functions to protect the mucosa from injury. Expression of TFF3 has been correlated with a poor prognosis in patients with cancer, but little is known about whether TFF3 directly contributes to the malignant behavior of cancer cells. The present study was conducted to determine whether TFF3 expression contributes to the malignant behavior of cancer cells in vitro and in vivo.
methodsTwo subclones of a metastatic rat colorectal cancer cell line, demonstrated previously to manifest aggressive (LN cells) and non-aggressive (LP cells) growth in vivo, were analyzed for expression of TFF3 and tested in assays of cancer cell migration, invasion, and apoptosis in vitro, and mortality in vivo.
resultsThe aggressive LN cell line endogenously expressed TFF3 and supported the transcription of a TFF3 promoter-driven reporter construct, whereas the non-aggressive LP cell line did not express TFF3. LN cells demonstrated enhanced migration, invasion, and less apoptosis compared to LP cells. Transfecting TFF3 into LP cells enhanced their ability to migrate, invade, block apoptosis, and behave more aggressively in vivo, thereby resembling the phenotype of LN cells.
conclusionsIn rat colon cancer cells, both endogenous and constitutive expression of TFF3 correlates with an aggressive phenotype. These data provide direct evidence that TFF3 contributes to the malignant behavior of cancer cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.